Health & Biotech
News
Tech Heavy: Maybe Big Tech is not what we’re cracking it up to be?
Health & Biotech
Weed Week: Cannabis stocks down almost 20% in 2023 but ECS Botanics showing resilience
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Stocks putting out good news, sneaking in bad news while almost everyone watches the cricket
Health & Biotech
Part 1: ASX biotechs with catalysts looking to pop in 2024
Health & Biotech
Weed Week: Cannabis stocks down almost 20pc in 2023, but here’s why they could rebound by Q2 2024
Health & Biotech
Neurotech completes recruitment in Phase 2/3 autism spectrum disorder trial
Health & Biotech
Melodiol’s FY23 revenue exceeds $20m as acquisition strategy proves successful
Experts
Dr Boreham’s Crucible: Excessive sweater? Botanix is here to get you fit for public consumption again
Health & Biotech
ASX Health Stocks: Imagion and Microba’s positive Phase 1 results; and LGP’s first mover advantage in France
Health & Biotech
The ASX stocks hoping to profit from the endless search for an ‘elixir of youth’
Health & Biotech
Weed Week: Cannabis boom a ‘matter of when, not if’; and NSW to allow residents to grow pot
Health & Biotech
Neurotech to extend Phase 2/3 autism spectrum disorder trial to adults
Health & Biotech
ASX Health Winners: Biotechs up 10pc in November, and Janus Henderson’s prediction for 2024
Health & Biotech
Check Up: Imugene’s oncolytic virus VAXINIA granted FDA’s Fast Track, but how effective is this novel therapy?
Health & Biotech
Melodiol enjoys milestone 2023 as subsidiaries bank profits
Health & Biotech